Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1995 Mar;2(2):126-31.
doi: 10.1007/BF02303627.

Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): a 10-year experience

Affiliations
Comparative Study

Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): a 10-year experience

J N Vauthey et al. Ann Surg Oncol. 1995 Mar.

Abstract

Background: Prior studies have shown a high rate of local recurrence and a dismal overall prognosis in malignant peripheral nerve sheath tumors (MPNSTs).

Methods: Thirty-three patients who had undergone primary treatment for localized extremity MPNSTs between 1982 and 1992 were reviewed. These cases were derived from a prospective database of 890 adult extremity soft-tissue sarcomas (STS). MPNSTs were compared with other extremity STS.

Results: MPNSTs were more often high grade and deep compared with other extremity STS (94% vs. 72% [p = 0.009] and 97% vs. 76% [p = 0.01], respectively). Location (upper or lower extremity), size (> 5 cm vs. < or = 5 cm), and status of margins after surgical resection (positive or negative for disease) did not differ between the two groups. When deep and high-grade MPNSTs were compared with deep and high-grade STS, a more aggressive local treatment was applied to MPNSTs with a higher number of amputations for MPNSTs (32%) compared with STS (9%; p < 0.001). In order to obtain adequate margins, 16 of 21 MPNSTs arising from major nerves required either amputation (n = 8) or nerve resection (n = 8). Adjuvant radiotherapy was used in 48% of deep and high-grade MPNSTs, and 3-year local disease-free survival was 70%. Survival of deep and high-grade MPNSTs was comparable with other deep and high-grade STS (3-year survival 50% vs. 69%, respectively; p = 0.1).

Conclusion: MPNSTs show adverse clinicopathologic features compared with other STS. However, when treated aggressively, MPNSTs have an outcome similar to other deep and high-grade extremity STS.

PubMed Disclaimer

References

    1. CA Cancer J Clin. 1992 Jul-Aug;42(4):241-54 - PubMed
    1. Cancer. 1981 May 15;47(10):2503-9 - PubMed
    1. Ann Surg. 1991 Sep;214(3):328-36; discussion 336-8 - PubMed
    1. Cancer. 1973 Jan;31(1):184-90 - PubMed
    1. J Clin Oncol. 1987 Apr;5(4):601-12 - PubMed

Publication types

MeSH terms